Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Novel activities of safe-in-human broad-spectrum antiviral agents.

Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D.

Antiviral Res. 2018 Jun;154:174-182. doi: 10.1016/j.antiviral.2018.04.016. Epub 2018 Apr 23.

PMID:
29698664
2.

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S.

Nat Commun. 2018 Apr 19;9(1):1567. doi: 10.1038/s41467-018-03987-2.

3.

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.

Huvila J, Laajala TD, Edqvist PH, Mardinoglu A, Talve L, Pontén F, Grénman S, Carpén O, Aittokallio T, Auranen A.

Gynecol Oncol. 2018 Apr;149(1):173-180. doi: 10.1016/j.ygyno.2018.02.016. Epub 2018 Mar 2.

PMID:
29486992
4.

Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.

He L, Tang J, Andersson EI, Timonen S, Koschmieder S, Wennerberg K, Mustjoki S, Aittokallio T.

Cancer Res. 2018 May 1;78(9):2407-2418. doi: 10.1158/0008-5472.CAN-17-3644. Epub 2018 Feb 26.

PMID:
29483097
5.

Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis.

Heinosalo T, Gabriel M, Kallio L, Adhikari P, Huhtinen K, Laajala TD, Kaikkonen E, Mehmood A, Suvitie P, Kujari H, Aittokallio T, Perheentupa A, Poutanen M.

Hum Reprod. 2018 May 1;33(5):817-831. doi: 10.1093/humrep/dey026.

PMID:
29462326
6.

Methods for High-throughput Drug Combination Screening and Synergy Scoring.

He L, Kulesskiy E, Saarela J, Turunen L, Wennerberg K, Aittokallio T, Tang J.

Methods Mol Biol. 2018;1711:351-398. doi: 10.1007/978-1-4939-7493-1_17.

PMID:
29344898
7.

Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions.

Tang J, Tanoli ZU, Ravikumar B, Alam Z, Rebane A, Vähä-Koskela M, Peddinti G, van Adrichem AJ, Wakkinen J, Jaiswal A, Karjalainen E, Gautam P, He L, Parri E, Khan S, Gupta A, Ali M, Yetukuri L, Gustavsson AL, Seashore-Ludlow B, Hersey A, Leach AR, Overington JP, Repasky G, Wennerberg K, Aittokallio T.

Cell Chem Biol. 2018 Feb 15;25(2):224-229.e2. doi: 10.1016/j.chembiol.2017.11.009. Epub 2017 Dec 21.

8.

Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery.

Ravikumar B, Aittokallio T.

Expert Opin Drug Discov. 2018 Feb;13(2):179-192. doi: 10.1080/17460441.2018.1413089. Epub 2017 Dec 12.

PMID:
29233023
9.

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.

Ali M, Khan SA, Wennerberg K, Aittokallio T.

Bioinformatics. 2018 Apr 15;34(8):1353-1362. doi: 10.1093/bioinformatics/btx766.

10.

Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.

Knuuttila M, Mehmood A, Huhtaniemi R, Yatkin E, Häkkinen MR, Oksala R, Laajala TD, Ryberg H, Handelsman DJ, Aittokallio T, Auriola S, Ohlsson C, Laiho A, Elo LL, Sipilä P, Mäkelä SI, Poutanen M.

Am J Pathol. 2018 Jan;188(1):216-228. doi: 10.1016/j.ajpath.2017.08.036. Epub 2017 Nov 7.

PMID:
29126837
11.

A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines.

Gönen M, Weir BA, Cowley GS, Vazquez F, Guan Y, Jaiswal A, Karasuyama M, Uzunangelov V, Wang T, Tsherniak A, Howell S, Marbach D, Hoff B, Norman TC, Airola A, Bivol A, Bunte K, Carlin D, Chopra S, Deran A, Ellrott K, Gopalacharyulu P, Graim K, Kaski S, Khan SA, Newton Y, Ng S, Pahikkala T, Paull E, Sokolov A, Tang H, Tang J, Wennerberg K, Xie Y, Zhan X, Zhu F; Broad-DREAM Community, Aittokallio T, Mamitsuka H, Stuart JM, Boehm JS, Root DE, Xiao G, Stolovitzky G, Hahn WC, Margolin AA.

Cell Syst. 2017 Nov 22;5(5):485-497.e3. doi: 10.1016/j.cels.2017.09.004. Epub 2017 Oct 4.

PMID:
28988802
12.

The inconvenience of data of convenience: computational research beyond post-mortem analyses.

Azencott CA, Aittokallio T, Roy S; DREAM Idea Challenge Consortium, Norman T, Friend S, Stolovitzky G, Goldenberg A.

Nat Methods. 2017 Sep 29;14(10):937-938. doi: 10.1038/nmeth.4457. No abstract available.

PMID:
28960198
13.

Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.

Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, Kainov DE.

Viruses. 2017 Sep 25;9(10). pii: E271. doi: 10.3390/v9100271.

14.

MediSyn: uncertainty-aware visualization of multiple biomedical datasets to support drug treatment selection.

He C, Micallef L, Tanoli ZU, Kaski S, Aittokallio T, Jacucci G.

BMC Bioinformatics. 2017 Sep 13;18(Suppl 10):393. doi: 10.1186/s12859-017-1785-7.

15.

In Search of System-Wide Productivity Gains - The Role of Global Collaborations in Preclinical Translation.

Ussi AE, de Kort M, Coussens NP, Aittokallio T, Hajduch M.

Clin Transl Sci. 2017 Nov;10(6):423-425. doi: 10.1111/cts.12498. Epub 2017 Sep 19. No abstract available.

PMID:
28929592
16.

Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression.

Ammad-Ud-Din M, Khan SA, Wennerberg K, Aittokallio T.

Bioinformatics. 2017 Jul 15;33(14):i359-i368. doi: 10.1093/bioinformatics/btx266.

17.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Andersson EI, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf TH, Kytölä S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S.

Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.

PMID:
28804127
18.

Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors.

Cichonska A, Ravikumar B, Parri E, Timonen S, Pahikkala T, Airola A, Wennerberg K, Rousu J, Aittokallio T.

PLoS Comput Biol. 2017 Aug 7;13(8):e1005678. doi: 10.1371/journal.pcbi.1005678. eCollection 2017 Aug.

19.

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA.

Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15.

PMID:
28619982
20.

Early metabolic markers identify potential targets for the prevention of type 2 diabetes.

Peddinti G, Cobb J, Yengo L, Froguel P, Kravić J, Balkau B, Tuomi T, Aittokallio T, Groop L.

Diabetologia. 2017 Sep;60(9):1740-1750. doi: 10.1007/s00125-017-4325-0. Epub 2017 Jun 8.

21.

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells.

Jaiswal A, Peddinti G, Akimov Y, Wennerberg K, Kuznetsov S, Tang J, Aittokallio T.

Genome Med. 2017 Jun 1;9(1):51. doi: 10.1186/s13073-017-0440-2.

22.

Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner.

Posada IMD, Lectez B, Sharma M, Oetken-Lindholm C, Yetukuri L, Zhou Y, Aittokallio T, Abankwa D.

Oncotarget. 2017 Jul 4;8(27):44550-44566. doi: 10.18632/oncotarget.17819.

23.
24.

Matched preclinical designs for improved translatability.

Aittokallio T, Scherer A, Poutanen M, Freedman LP.

Sci Transl Med. 2017 May 10;9(389). pii: eaal4101. doi: 10.1126/scitranslmed.aal4101.

PMID:
28490671
25.

C-SPADE: a web-tool for interactive analysis and visualization of drug screening experiments through compound-specific bioactivity dendrograms.

Ravikumar B, Alam Z, Peddinti G, Aittokallio T.

Nucleic Acids Res. 2017 Jul 3;45(W1):W495-W500. doi: 10.1093/nar/gkx384.

26.

SynergyFinder: a web application for analyzing drug combination dose-response matrix data.

Ianevski A, He L, Aittokallio T, Tang J.

Bioinformatics. 2017 Aug 1;33(15):2413-2415. doi: 10.1093/bioinformatics/btx162.

27.

Whole-genome view of the consequences of a population bottleneck using 2926 genome sequences from Finland and United Kingdom.

Chheda H, Palta P, Pirinen M, McCarthy S, Walter K, Koskinen S, Salomaa V, Daly M, Durbin R, Palotie A, Aittokallio T, Ripatti S.

Eur J Hum Genet. 2017 Apr;25(4):477-484. doi: 10.1038/ejhg.2016.205. Epub 2017 Feb 1.

28.

Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.

Haltia UM, Andersson N, Yadav B, Färkkilä A, Kulesskiy E, Kankainen M, Tang J, Bützow R, Riska A, Leminen A, Heikinheimo M, Kallioniemi O, Unkila-Kallio L, Wennerberg K, Aittokallio T, Anttonen M.

Gynecol Oncol. 2017 Mar;144(3):621-630. doi: 10.1016/j.ygyno.2016.12.016. Epub 2017 Jan 16.

PMID:
28104295
29.

Consistency in drug response profiling.

Mpindi JP, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, Hirasawa A, Kangaspeska S, Wennerberg K, Kallioniemi O, Aittokallio T.

Nature. 2016 Nov 30;540(7631):E5-E6. doi: 10.1038/nature20171. No abstract available.

PMID:
27905421
30.

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.

Guinney J, Wang T, Laajala TD, Winner KK, Bare JC, Neto EC, Khan SA, Peddinti G, Airola A, Pahikkala T, Mirtti T, Yu T, Bot BM, Shen L, Abdallah K, Norman T, Friend S, Stolovitzky G, Soule H, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Xie Y, Aittokallio T, Zhou FL, Costello JC; Prostate Cancer Challenge DREAM Community.

Lancet Oncol. 2017 Jan;18(1):132-142. doi: 10.1016/S1470-2045(16)30560-5. Epub 2016 Nov 16.

31.

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.

Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, Karjalainen R, Majumder MM, Ojamies P, Pemovska T, Wennerberg K, Heckman C, Porkka K, Wolf M, Aittokallio T, Kallioniemi O.

Leukemia. 2017 May;31(5):1187-1195. doi: 10.1038/leu.2016.314. Epub 2016 Nov 11.

32.

Erratum: Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.

Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VS, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bellón V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C; Members of the Rheumatoid Arthritis Challenge Consortium, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TW, Kurreeman F, Allaart CF, Bridges SL Jr, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM.

Nat Commun. 2016 Oct 10;7:13205. doi: 10.1038/ncomms13205. No abstract available.

33.

Orphan G protein-coupled receptor GPRC5A modulates integrin β1-mediated epithelial cell adhesion.

Bulanova DR, Akimov YA, Rokka A, Laajala TD, Aittokallio T, Kouvonen P, Pellinen T, Kuznetsov SG.

Cell Adh Migr. 2017 Sep 3;11(5-6):434-446. doi: 10.1080/19336918.2016.1245264. Epub 2017 Feb 6.

34.

Multi-Omics Studies towards Novel Modulators of Influenza A Virus-Host Interaction.

Söderholm S, Fu Y, Gaelings L, Belanov S, Yetukuri L, Berlinkov M, Cheltsov AV, Anders S, Aittokallio T, Nyman TA, Matikainen S, Kainov DE.

Viruses. 2016 Sep 29;8(10). pii: E269. Review.

35.

Drug response prediction by inferring pathway-response associations with kernelized Bayesian matrix factorization.

Ammad-Ud-Din M, Khan SA, Malani D, Murumägi A, Kallioniemi O, Aittokallio T, Kaski S.

Bioinformatics. 2016 Sep 1;32(17):i455-i463. doi: 10.1093/bioinformatics/btw433.

PMID:
27587662
36.

Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.

Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VS, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bellón V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C; Members of the Rheumatoid Arthritis Challenge Consortium, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TW, Kurreeman F, Allaart CF, Louis Bridges S Jr, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM, Bridges SL, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM.

Nat Commun. 2016 Aug 23;7:12460. doi: 10.1038/ncomms12460.

37.

The Hydroxysteroid (17β) Dehydrogenase Family Gene HSD17B12 Is Involved in the Prostaglandin Synthesis Pathway, the Ovarian Function, and Regulation of Fertility.

Kemiläinen H, Adam M, Mäki-Jouppila J, Damdimopoulou P, Damdimopoulos AE, Kere J, Hovatta O, Laajala TD, Aittokallio T, Adamski J, Ryberg H, Ohlsson C, Strauss L, Poutanen M.

Endocrinology. 2016 Oct;157(10):3719-3730. Epub 2016 Aug 4.

PMID:
27490311
38.

Phosphoproteomics to Characterize Host Response During Influenza A Virus Infection of Human Macrophages.

Söderholm S, Kainov DE, Öhman T, Denisova OV, Schepens B, Kulesskiy E, Imanishi SY, Corthals G, Hintsanen P, Aittokallio T, Saelens X, Matikainen S, Nyman TA.

Mol Cell Proteomics. 2016 Oct;15(10):3203-3219. Epub 2016 Aug 2.

39.

Optimized design and analysis of preclinical intervention studies in vivo.

Laajala TD, Jumppanen M, Huhtaniemi R, Fey V, Kaur A, Knuuttila M, Aho E, Oksala R, Westermarck J, Mäkelä S, Poutanen M, Aittokallio T.

Sci Rep. 2016 Aug 2;6:30723. doi: 10.1038/srep30723.

40.

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.

Kangaspeska S, Hultsch S, Jaiswal A, Edgren H, Mpindi JP, Eldfors S, Brück O, Aittokallio T, Kallioniemi O.

BMC Cancer. 2016 Jul 4;16:378. doi: 10.1186/s12885-016-2452-5.

41.

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.

Gautam P, Karhinen L, Szwajda A, Jha SK, Yadav B, Aittokallio T, Wennerberg K.

Mol Cancer. 2016 May 10;15(1):34. doi: 10.1186/s12943-016-0517-3.

42.

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.

Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, Peehl DM, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Östling P, Af Hällström TM.

Eur Urol. 2017 Mar;71(3):319-327. doi: 10.1016/j.eururo.2016.04.019. Epub 2016 May 6.

43.

CIP2A Promotes T-Cell Activation and Immune Response to Listeria monocytogenes Infection.

Côme C, Cvrljevic A, Khan MM, Treise I, Adler T, Aguilar-Pimentel JA, Au-Yeung B, Sittig E, Laajala TD, Chen Y, Oeder S, Calzada-Wack J, Horsch M, Aittokallio T, Busch DH, Ollert MW, Neff F, Beckers J, Gailus-Durner V, Fuchs H, Hrabě de Angelis M, Chen Z, Lahesmaa R, Westermarck J.

PLoS One. 2016 Apr 21;11(4):e0152996. doi: 10.1371/journal.pone.0152996. eCollection 2016.

44.

Transcriptional response networks for elucidating mechanisms of action of multitargeted agents.

Kibble M, Khan SA, Saarinen N, Iorio F, Saez-Rodriguez J, Mäkelä S, Aittokallio T.

Drug Discov Today. 2016 Jul;21(7):1063-75. doi: 10.1016/j.drudis.2016.03.001. Epub 2016 Mar 12. Review.

PMID:
26979547
45.

Cancer stem cell drugs target K-ras signaling in a stemness context.

Najumudeen AK, Jaiswal A, Lectez B, Oetken-Lindholm C, Guzmán C, Siljamäki E, Posada IM, Lacey E, Aittokallio T, Abankwa D.

Oncogene. 2016 Oct 6;35(40):5248-5262. doi: 10.1038/onc.2016.59. Epub 2016 Mar 14.

46.

Liver lipid metabolism is altered by increased circulating estrogen to androgen ratio in male mouse.

Vehmas AP, Adam M, Laajala TD, Kastenmüller G, Prehn C, Rozman J, Ohlsson C, Fuchs H, Hrabě de Angelis M, Gailus-Durner V, Elo LL, Aittokallio T, Adamski J, Corthals G, Poutanen M, Strauss L.

J Proteomics. 2016 Feb 5;133:66-75. doi: 10.1016/j.jprot.2015.12.009. Epub 2015 Dec 9.

PMID:
26691839
47.

Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.

Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI.

Cancer Res. 2016 Feb 15;76(4):796-804. doi: 10.1158/0008-5472.CAN-15-2298. Epub 2015 Dec 18.

48.

Relevance Rank Platform (RRP) for Functional Filtering of High Content Protein-Protein Interaction Data.

Pokharel YR, Saarela J, Szwajda A, Rupp C, Rokka A, Lal Kumar Karna S, Teittinen K, Corthals G, Kallioniemi O, Wennerberg K, Aittokallio T, Westermarck J.

Mol Cell Proteomics. 2015 Dec;14(12):3274-83. doi: 10.1074/mcp.M115.050773. Epub 2015 Oct 23.

49.

Systematic Identification of MicroRNAs That Impact on Proliferation of Prostate Cancer Cells and Display Changed Expression in Tumor Tissue.

Aakula A, Kohonen P, Leivonen SK, Mäkelä R, Hintsanen P, Mpindi JP, Martens-Uzunova E, Aittokallio T, Jenster G, Perälä M, Kallioniemi O, Östling P.

Eur Urol. 2016 Jun;69(6):1120-8. doi: 10.1016/j.eururo.2015.09.019. Epub 2015 Oct 20.

PMID:
26489476
50.

From drug response profiling to target addiction scoring in cancer cell models.

Yadav B, Gopalacharyulu P, Pemovska T, Khan SA, Szwajda A, Tang J, Wennerberg K, Aittokallio T.

Dis Model Mech. 2015 Oct 1;8(10):1255-64. doi: 10.1242/dmm.021105.

Supplemental Content

Loading ...
Support Center